metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
MIBC - NA - all population muscular invasive bladder cancer (MIBC) MIBC - (neo)adjuvant (NA) MIBC - NA - all population
versus no additional treatment
	atezolizumab alone
	IMvigor-010, 2021 Urologe A 2016; 55:1491-1493 ESMO Immuno-Oncology Virtual Congress 2020 (9-12 December) Lancet Oncol 2021 Apr;22(4):525-537. The Lancet Oncology NCT02450331	RCT	MIBC - (neo)adjuvant (NA)	atezolizumab	observation	patients aged 18 years or older and had histologically confirmed muscle-invasiveurothelial carcinoma of either the bladder or the upper tract as Adjuvant Therapy (Participants With High-Risk Muscle-Invasive Urothelial Carcinoma)	406 / 403	some concern	inconclusive	inconclusive 11 % decrease in events or deaths (EFS),events or deaths (EFS) (PE)
versus placebo
	nivolumab alone
	CheckMate 274 (all population), 2017 Urologe A 2017; 56:1331-1332 Journal of Clinical Oncology 39, no. 6_suppl (February 20, 2021) 391-391. N Engl J Med 2021 Jun 3;384(22):2102-2114. NCT02632409	RCT	MIBC - NA - all population	nivolumab	placebo	adjuvant therapy patients with muscle-invasive high-risk urothelial carcinoma who had undergone radicalsurgery	353 / 356	low	conclusif	suggested 28 % decrease in RFS/DFS demonstrated 30 % decrease in events or deaths (EFS) (PE)
MIBC - NA - PDL1 positive muscular invasive bladder cancer (MIBC) MIBC - (neo)adjuvant (NA) MIBC - NA - PDL1 positive
versus placebo
	nivolumab alone
	CheckMate 274 (PDL1>1%), 2017 Urologe A 2017; 56:1331-1332 Journal of Clinical Oncology 39, no. 6_suppl (February 20, 2021) 391-391. N Engl J Med 2021 Jun 3;384(22):2102-2114. NCT02632409	RCT	MIBC - NA - PDL1 positive	nivolumab	placebo	adjuvant therapy patients with muscle-invasive high-risk urothelial carcinoma who had undergone radicalsurgery	140 / 142	low	conclusif	suggested 45 % decrease in RFS/DFS demonstrated 45 % decrease in events or deaths (EFS) (PE)